A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K.
A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003518:Cyclopenthiazide / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000008:administration & dosage*; D011188:Potassium / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D010096:Oxprenolol; D011188:Potassium; D003518:Cyclopenthiazide